GO
Loading...

Sanofi SA

More

  • European shares dip early as China data weighs Monday, 24 Mar 2014 | 5:22 AM ET

    *China's lower-than-expected PMI weighs on sentiment. PARIS, March 24- European stocks slipped in early trade on Monday, trimming last week's lofty gains, as data showing China's manufacturing activity contracted in the first quarter of 2014 revived worries over the outlook for global growth.

  • COPENHAGEN, March 20- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • Wider market sentiment was still undermined by the crisis in Ukraine, where confrontation between Kiev and Moscow showed no sign of easing. The DAX had fallen 2.9 percent in the previous two sessions, dragged down by worries about Ukraine and by disappointing Chinese trade data.

  • Wider market sentiment was still undermined by the crisis in Ukraine, where confrontation between Kiev and Moscow showed no sign of easing. The DAX had fallen 2.9 percent in the previous two sessions, dragged down by worries about Ukraine and by disappointing Chinese trade data.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • ZURICH, March 7- Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment with sales of $1 billion- plus.

  • Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee, more than four years after it first filed for approval.

  • Feb 25- Vivus Inc's silence on its strategy to boost sales of obesity drug Qsymia has increased doubts about whether the pill will reach its full commercial potential. Analysts said on Tuesday that Vivus, with its limited sales force, needed a partner to ensure the drug's success.

  • NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.

  • Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

  • *L'Oreal buys 8 pct stake from Nestle for 6.5 bln euros. *Nestle stake cut to 23 pct, but says in for long haul. *Deal will boost L'Oreal EPS, Nestle to do share buyback.

  • *L'Oreal does not need to sell Sanofi stake for Nestle deal. *Hopes recede for debt-funded buyback of stake by Sanofi.

  • *Bloomberg said Nestle looking to cut L'Oreal stake. Bloomberg reported on Friday that Swiss food group Nestle was looking at ways to reduce its L'Oreal stake, which is currently worth more than 23 billion euros.

  • L'Oreal's surge helps keep European shares steady Monday, 10 Feb 2014 | 7:27 AM ET

    LONDON, Feb 10- European shares traded flat on Monday, as cosmetics maker L'Oreal gained on expectations it will buy back its shares owned by Nestle and helped to keep the market steady after its recent gains.

  • PARIS, Feb 6- French drugmaker Sanofi's forecast for a return to profit growth after three years of decline failed to impress investors on Thursday, sending its shares to a one-year low.

  • Sanofi CEO: We underperformed in EM in 2013 Thursday, 6 Feb 2014 | 8:10 AM ET

    The CEO of Sanofi admitted the pharmaceutical giant underperformed in emerging markets last year, after reporting a decline in quarterly sales.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.